We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| China Dasheng Biotechnology Company (PK) | USOTC:CDBT | OTCMarkets | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.0233 | -46.60% | 0.0267 | 0.0267 | 0.069 | 0.0267 | 0.0267 | 0.0267 | 100 | 21:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
___________
FORM 8-K
___________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 28, 2009
Commission File Number: 333- 141327
CHINA DASHENG BIOTECHNOLOGY COMPANY
(Exact name of small business issuer as specified in its charter)
Nevada
26-0162321
(State or other jurisdiction of incorporation or organization)
(IRS Employer Identification No.)
China Dasheng Biotechnology Company
Building B 17th Floor
Century Plaza
Qingyang Road
Lanzhou, Gansu
People's Republic of China
Telephone number: (86)931 8441248
(Address of principal executive offices including Zip Code)
Gang Chen
China Dasheng Biotechnology Company
Building B 17th Floor
Century Plaza
Qingyang Road
Lanzhou, Gansu
People's Republic of China
Telephone number: (86)931 8441248
(Agent's office and telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 28, 2009, the Board of Directors of China Dasheng Biotechnology (the “Company”) appointed Mr. Gang Chen as Chairman of the Board and Chief Executive Officer and the Company. On the same day Mr. Jinjun Qi resigned as Chairman of the Board and a director and Sidong Zhang resigned as Chief Executive Officer and as a director. The resignations were not as a result of any disagreements with us.
Mr. Gang Chen, age 46, has been employed by the Company’s subsidiary Dasheng Biotechnology since June 1986 and prior thereto was president of Gangsu Ritong Electronic Company from 1999 to 2008. Mr. Gang received a BA in economics and management in 1984 from Lanzhou University in 1991.
The Company has not entered into any employment agreements with Mr. Gang Chen.
Item 9.01 Financial Statements And Exhibits.
(a) Financial Statements of Business Acquired. None
(b) Pro Forma Financial Information. None
(c) Shell Company Transactions. None
(d) Exhibits. None
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 6, 2009
CHINA DASHENG BIOTECHNOLOGY COMPANY
By: /s/ Gang Chen
Name: Gang Chen
Title: CEO
1 Year China Dasheng Biotechnol... (PK) Chart |
1 Month China Dasheng Biotechnol... (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
